IDN5706 inhibits synovial inflammation via inducing M2 polarization of synovial macrophages in osteoarthritis rats.

Abstract

IDN5706 is a tetrahydro derivative of hyperforin. In this study, we aimed to explore the effect of IDN5706 on synovial macrophages in osteoarthritis (OA) rats, and the underlying mechanisms. OA rats were employed for the in vivo experiments, and RAW264.7 cells were employed for the in vitro experiments. Histopathological changes in synovium were examined using hematoxylin and eosin (HE) staining; Cell apoptosis in synovium was assessed by TUNEL staining; Macrophages polarization was determined by immunohistochemical analysis and flow cytometry; The mRNA expression and protein level of genes were detected by qRT-PCR and western blot; The efferocytosis of macrophages was assessed by flow cytometry. IDN5706 reversed the increased CD86-positive cells (M1 macrophages) and decreased CD206-positive cells (M2 macrophages), both in synovium and synovial fluid of OA rats. The in vitro experiments further confirmed the promotion effect of IDN5706 on M2 macrophages, accompanied by the elevated Arg-1 and reduced iNOS. Also, the up-regulated p-mTOR in synovium and synovial fluid of OA rats were reversed by IDN5706, and the decreased M1 macrophages and increased M2 macrophages induced by IDN5706 were reversed by mTOR activator. IDN5706 enhanced the efferocytosis of IL-4 treated RAW264.7 cells, and the animal experiments further revealed the involvement of efferocytosis in the improvement of OA by IDN5706. IDN5706 enhanced the efferocytosis of synovial macrophages by inducing M2 polarization via inhibiting p-mTOR, thus suppressing synovial inflammation and OA development, providing a theoretical basis for IDN5706 as a clinical drug for inflammatory diseases.